[68Ga]Ga-DPI-4452 PET/CT在透明细胞肾细胞癌中的诊断效能:一项前瞻性试验
结果显示,其对原发透明细胞肾细胞癌的灵敏度和特异度分别为100%和85.7%,对肾外转移灶的灵敏度为97.7%,较常规影像多检出82.6%的病灶,且示踪剂摄取与组织CAIX H评分强相关(r=0.83,P<0.0001)。
要点
- 对原发透明细胞肾细胞癌诊断灵敏度100%、特异度85.7%。
- 对肾外转移灶灵敏度97.7%,较常规影像多检出82.6%病灶。
- 示踪剂摄取与组织CAIX表达强相关(r=0.83,P<0.0001)。
核心结论
- [68Ga]Ga-DPI-4452 PET/CT耐受性良好,在识别原发透明细胞肾细胞癌和检出转移性疾病方面表现出良好性能,并可反映组织CAIX表达。
主要发现
- 对原发透明细胞肾细胞癌的灵敏度为100%、特异度为85.7%。
- 对肾外转移灶的灵敏度为97.7%,较常规影像多检出82.6%的病灶。
- 示踪剂摄取与组织CAIX H评分强相关(r=0.83,P<0.0001)。
- 除原发灶外,检出20个常规影像遗漏的转移灶,扣除1个PET阴性的肝转移后净增19个病灶,并对静脉血栓存活性提供补充生物学表征。
临床怎么用
- 该示踪剂PET/CT可用于疑似肾肿块患者的原发透明细胞肾细胞癌识别及转移灶检出,并辅助评估CAIX表达与血栓存活性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preoperative identification and staging of clear cell renal cell carcinoma (ccRCC) are challenging. We prospectively evaluated [68Ga]Ga-DPI-4452, a carbonic anhydrase IX (CAIX)-targeted tracer, for same-day PET/CT. Methods: Adults with suspected renal masses scheduled for surgery or biopsy underwent [68Ga]Ga-DPI-4452 PET/CT. Histopathology or composite follow-up served as the reference standard. Results: Thirty patients were enrolled (23 with ccRCC; 7 with non-ccRCC/benign lesions). No tracer-related adverse events occurred. [68Ga]Ga-DPI-4452 PET/CT identified primary ccRCC with 100% sensitivity and 85.7% specificity. For extrarenal metastases, [68Ga]Ga-DPI-4452 PET/CT achieved a sensitivity of 97.7% and detected 82.6% more lesions than did conventional imaging. Tracer uptake was strongly correlated with tissue CAIX H-score (r = 0.83, P < 0.0001). Beyond primary lesions, [68Ga]Ga-DPI-4452 PET/CT detected 20 metastases missed by conventional imaging, resulting in a net increase of 19 lesions after accounting for 1 PET-negative hepatic metastasis, and provided complementary biologic characterization of venous thrombi viability. Conclusion: [68Ga]Ga-DPI-4452 PET/CT was well-tolerated and showed promising performance in identifying primary ccRCC and detecting metastatic disease, while also reflecting tissue CAIX expression.
引用
- Wang D, Du L, Wang Y, et al. Diagnostic Performance of [68Ga]Ga-DPI-4452 PET/CT in Patients with Clear Cell Renal Cell Carcinoma: A Prospective Trial. J Nucl Med. 2026. PMID: 42722441. doi:10.2967/jnumed.126.272990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。